51
|
Abstract
Many patients with Parkinson's disease (PD) complain about sleep disturbances. These symptoms originate from motor symptoms, nocturnal problems, psychiatric symptoms, and other sleep disorders including Excessive daytime sleepiness (EDS), REM sleep behavior disorder (RBD), Restless legs syndrome (RLS), and Sleep apnea syndrome (SAS). Especially, RBD is paid attention to prodromal symptoms of PD. Also, one third of patients with PD have RBD symptoms. Moreover, RBD is one of aggravating factors of motor symptoms, autonomic dysfunctions, and dementia. Now, the evidence based medicine for sleep disturbances is lack in patients with PD. We need to evaluate various causes of sleep disturbances in detail and deal with individuals.
Collapse
Affiliation(s)
- Takashi Nomura
- Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine , Tottori University
| | | | | |
Collapse
|
52
|
Minimal Clinically Important Difference on Parkinson's Disease Sleep Scale 2nd Version. PARKINSONS DISEASE 2015; 2015:970534. [PMID: 26539303 PMCID: PMC4619979 DOI: 10.1155/2015/970534] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 06/28/2015] [Accepted: 09/10/2015] [Indexed: 11/30/2022]
Abstract
Background and Aims. The aim of the present study was to determine the estimates of minimal clinically important difference for Parkinson's Disease Sleep Scale 2nd version (PDSS-2) total score and dimensions. Methods. The subject population consisted of 413 PD patients. At baseline, MDS-UPDRS, Hoehn-Yahr Scale, Mattis Dementia Rating Scale, and PDSS-2 were assessed. Nine months later the PDSS-2 was reevaluated with the Patient-Reported Global Impression Improvement Scale. Both anchor-based techniques (within patients' score change method and sensitivity- and specificity-based method by receiver operating characteristic analysis) and distribution-based approaches (effect size calculations) were utilized to determine the magnitude of minimal clinically important difference. Results. According to our results, any improvements larger than −3.44 points or worsening larger than 2.07 points can represent clinically important changes for the patients. These thresholds have the effect size of 0.21 and −0.21, respectively. Conclusions. Minimal clinically important differences are the smallest change of scores that are subjectively meaningful to patients. Studies using the PDSS-2 as outcome measure should utilize the threshold of −3.44 points for detecting improvement or the threshold of 2.07 points for observing worsening.
Collapse
|
53
|
Restless Legs Syndrome and Leg Motor Restlessness in Parkinson's Disease. PARKINSONS DISEASE 2015; 2015:490938. [PMID: 26504610 PMCID: PMC4609490 DOI: 10.1155/2015/490938] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 11/25/2014] [Revised: 04/05/2015] [Accepted: 04/06/2015] [Indexed: 01/15/2023]
Abstract
Sleep disturbances are important nonmotor symptoms in Parkinson's disease (PD) that are associated with a negative impact on quality of life. Restless legs syndrome (RLS), which is characterized by an urge to move the legs accompanied by abnormal leg sensations, can coexist with PD, although the pathophysiology of these disorders appears to be different. RLS and PD both respond favorably to dopaminergic treatment, and several investigators have reported a significant relationship between RLS and PD. Sensory symptoms, pain, motor restlessness, akathisia, and the wearing-off phenomenon observed in PD should be differentiated from RLS. RLS in PD may be confounded by chronic dopaminergic treatment; thus, more studies are needed to investigate RLS in drug-naïve patients with PD. Recently, leg motor restlessness (LMR), which is characterized by an urge to move the legs that does not fulfill the diagnostic criteria for RLS, has been reported to be observed more frequently in de novo patients with PD than in age-matched healthy controls, suggesting that LMR may be a part of sensorimotor symptoms intrinsic to PD. In this paper, we provide an overview of RLS, LMR, and PD and of the relationships among these disorders.
Collapse
|
54
|
Abstract
Sleep disturbances are a common non-motor feature in patients with Parkinson's disease (PD). Early diagnosis and appropriate management are imperative for enhancing patient quality of life. Sleep disturbances can be caused by multiple factors in addition to age-related changes in sleep, such as nocturnal motor symptoms (rigidity, resting tremor, akinesia, tardive dyskinesia, and the "wearing off" phenomenon), non-motor symptoms (pain, hallucination, and psychosis), nocturia, and medication. Disease-related pathology involving the brainstem and changes in the neurotransmitter systems (norepinephrine, serotonin, and acetylcholine) responsible for regulating sleep structure and the sleep/wake cycle play a role in emerging excessive daytime sleepiness and sleep disturbances. Additionally, screening for sleep apnea syndrome, rapid eye movement sleep behavior disorder, and restless legs syndrome is clinically important. Questionnaire-based assessment utilizing the PD Sleep Scale-2 is useful for screening PD-related nocturnal symptoms. In this review, we focus on the current understanding and management of sleep disturbances in PD.
Collapse
|
55
|
Suzuki K, Miyamoto T, Miyamoto M, Suzuki S, Numao A, Watanabe Y, Tatsumoto M, Sakuta H, Watanabe Y, Fujita H, Iwanami M, Sada T, Kadowaki T, Hashimoto K, Trenkwalder C, Hirata K. Evaluation of cutoff scores for the Parkinson's disease sleep scale-2. Acta Neurol Scand 2015; 131:426-30. [PMID: 25402773 DOI: 10.1111/ane.12347] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/08/2014] [Indexed: 11/27/2022]
Abstract
BACKGROUND The Parkinson's Disease Sleep Scale (PDSS)-2 is a recently developed tool for evaluating disease-related nocturnal disturbances in patients with Parkinson's disease (PD). However, its cutoff score has not been clinically assessed. We determined the optimal cutoff score of the Japanese version of the PDSS-2. METHODS Patients with PD (n = 146) and controls (n = 100) completed the PDSS-2 and the Pittsburgh Sleep Quality Index (PSQI). Poor sleepers were defined as having global PSQI scores >5. Optimal cutoff scores for determining poor sleepers were assessed using the receiver operating characteristic curve. RESULTS A PDSS-2 total score ≥ 14 exhibited 82.0% sensitivity and 70.6% specificity, whereas a PDSS-2 total score ≥ 15 provided 72.1% sensitivity and 72.9% specificity in distinguishing poor sleepers (PSQI score >5) from good sleepers (PSQI ≤ 5). Nocturnal disturbances were more frequently observed in patients with PD than in controls (PDSS-2 total score ≥ 14 or ≥ 15; 51.4% vs 20%; 45.9% vs 19%). Nocturnal disturbances were associated with higher Hoehn and Yahr stages and Unified Parkinson's Disease Rating Scale motor scores, impaired quality of life, daytime sleepiness, and depressive symptoms. CONCLUSION We suggest that PDSS-2 total scores ≥ 15 are useful for detecting poor sleepers among patients with PD.
Collapse
Affiliation(s)
- K. Suzuki
- Department of Neurology; Dokkyo Medical University; Tochigi Japan
| | - T. Miyamoto
- Department of Neurology; Dokkyo Medical University Koshigaya Hospital; Saitama Japan
| | - M. Miyamoto
- Department of Neurology; Dokkyo Medical University; Tochigi Japan
| | - S. Suzuki
- Department of Neurology; Dokkyo Medical University; Tochigi Japan
| | - A. Numao
- Department of Neurology; Dokkyo Medical University; Tochigi Japan
| | - Y. Watanabe
- Department of Neurology; Dokkyo Medical University; Tochigi Japan
| | - M. Tatsumoto
- Department of Neurology; Dokkyo Medical University; Tochigi Japan
| | - H. Sakuta
- Department of Neurology; Dokkyo Medical University; Tochigi Japan
| | - Y. Watanabe
- Department of Neurology; Dokkyo Medical University; Tochigi Japan
| | - H. Fujita
- Department of Neurology; Dokkyo Medical University; Tochigi Japan
| | - M. Iwanami
- Department of Neurology; Dokkyo Medical University Koshigaya Hospital; Saitama Japan
| | - T. Sada
- Department of Neurology; Dokkyo Medical University; Tochigi Japan
| | - T. Kadowaki
- Department of Neurology; Dokkyo Medical University; Tochigi Japan
| | - K. Hashimoto
- Department of Neurology; Dokkyo Medical University; Tochigi Japan
| | - C. Trenkwalder
- Department of Neurosurgery; University of Göttingen; Göttingen Germany
- Paracelsus-Elena Hospital; Kassel Germany
| | - K. Hirata
- Department of Neurology; Dokkyo Medical University; Tochigi Japan
| |
Collapse
|
56
|
Yu RL, Tan CH, Wu RM. The impact of nocturnal disturbances on daily quality of life in patients with Parkinson's disease. Neuropsychiatr Dis Treat 2015; 11:2005-12. [PMID: 26273203 PMCID: PMC4532217 DOI: 10.2147/ndt.s85483] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
OBJECTIVES The aims of this study were to explore nocturnal disturbances in patients with Parkinson's disease (PD) and to assess their impact on quality of life (QoL). METHODS A total of 211 patients with PD were recruited for this study, and each participant was evaluated using the mini-mental state examination, PD sleep scale - second version (PDSS-2), pittsburgh sleep quality index (PSQI), PD QoL questionnaire (PDQ), Epworth sleepiness scale, Hoehn and Yahr (H&Y) staging, and unified Parkinson's disease rating scale (UPDRS). Multiple regression analyses were performed to determine the contribution of the predictive variables on QoL. RESULTS There were 56.4% males (mean age: 64.08 years; disease duration: 6.02 years; H&Y stage: 2.25; and UPDRS: 33.01) in this study. Our patients' actual sleep time was 5.96±1.16 hours and the average sleep efficiency was 82.93%±12.79%. Up to 64.4% of patients were classified as "poor" sleepers and 23.8% suffered from daytime sleepiness. The final stepwise regression model revealed that UPDRS parts I and II, the sleep disturbance and daytime dysfunction components of the PSQI, the PD symptoms at night subscale of the PDSS-2, and the levodopa equivalent dose were significant predictors of the PDQ score (R (2)=53, F 7,165=28.746; P<0.001). CONCLUSION Most of the PD patients have sleep problems, and nearly one-quarter of them have abnormal daytime somnolence. The nocturnal disturbances were found to result in worse QoL in PD patients. Ethnicity-specific effects of susceptibility to sleep disturbances were discussed, and these results also highlighted the direction for further studies to explore when examining effective management programs toward these disturbances.
Collapse
Affiliation(s)
- Rwei-Ling Yu
- Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - Chun-Hsiang Tan
- Wolfson Centre for Age Related Diseases, King's College London, London, UK
| | - Ruey-Meei Wu
- Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan
| |
Collapse
|
57
|
Rijsman RM, Schoolderman LF, Rundervoort RS, Louter M. Restless legs syndrome in Parkinson's disease. Parkinsonism Relat Disord 2014; 20 Suppl 1:S5-9. [PMID: 24262188 DOI: 10.1016/s1353-8020(13)70004-x] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The Restless legs syndrome (RLS) and Parkinson's disease (PD) are two disorders that can co-exist, whether or not they share a common pathophysiology. If, and to what extent RLS and PD share the same pathophysiology, is still under debate. Sleep disturbances are prevalent in PD, and as PD progresses, nocturnal disturbances become even more evident, in association not only with motor symptoms but also with non-motor symptoms. Alertness to, and recognition of, RLS in PD patients with sleep disorders could improve customized treatment and quality of life of these patients. In this article the prevalence of RLS in PD, the clinical profile of RLS in PD, the PD profile of patients with RLS, RLS mimics specifically related to PD and impact of RLS in PD will be reviewed.
Collapse
Affiliation(s)
- Roselyne M Rijsman
- Center of Sleep and Wake Disorders and Department of Neurology, Medical Center Haaglanden, The Hague, The Netherlands
| | | | | | | |
Collapse
|
58
|
Calzetti S, Angelini M, Negrotti A, Marchesi E, Goldoni M. A long-term prospective follow-up study of incident RLS in the course of chronic DAergic therapy in newly diagnosed untreated patients with Parkinson's disease. J Neural Transm (Vienna) 2013; 121:499-506. [PMID: 24357050 DOI: 10.1007/s00702-013-1132-8] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2013] [Accepted: 11/29/2013] [Indexed: 11/24/2022]
Abstract
It is currently controversial if and in which terms Parkinson's disease (PD) and restless legs syndrome (RLS) are linked in co-morbid association. In a cohort of 106 de novo PD patients (67 male and 39 female, aged 42-83 years), 15 of them developed RLS, which was prospectively assessed at 6-month intervals from the starting of dopamine(DA)ergic therapy. The incidence rate of total RLS was 47 per 1,000 case/person per year and 37 per 1,000 case/person per year after the exclusion of possible "secondary" forms of the disorder (n = 3). These figures are higher than those reported in an incidence study conducted in German general population (Study of Health in Pomerania), in which the method of ascertainment of RLS similar to ours has been used. An incidence rate of total RLS significantly higher than that reported in the above-mentioned study was found in the age ranges 55-64 years and in the age range 45-74 years standardized to European general population 2013 (70 and 53 per 1,000 case/person per year, respectively, p < 0.01). Ten out of 12 patients (83.3 %) developed RLS within 24 months from the starting of DAergic medication (median latency 7.5 months). These findings support the view that sustained DAergic therapy could represent the critical factor inducing an increased incidence of RLS in patients with PD and that the latter disease should be regarded as the condition predisposing to the occurrence of the former and not viceversa as previously hypothesized. The mechanism underlying the increased incidence of RLS remains unclear and deserves further investigation.
Collapse
Affiliation(s)
- Stefano Calzetti
- Neurology Unit, Department of Neurosciences, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy,
| | | | | | | | | |
Collapse
|
59
|
Sleep disturbance in patients with Parkinson's disease presenting with leg motor restlessness. Parkinsonism Relat Disord 2013; 19:571-2. [PMID: 23466058 DOI: 10.1016/j.parkreldis.2013.02.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/12/2012] [Revised: 01/28/2013] [Accepted: 02/07/2013] [Indexed: 11/22/2022]
|
60
|
Suzuki K, Miyamoto T, Miyamoto M, Watanabe Y, Suzuki S, Tatsumoto M, Iwanami M, Sada T, Kadowaki T, Numao A, Hashimoto K, Sakuta H, Hirata K. Probable rapid eye movement sleep behavior disorder, nocturnal disturbances and quality of life in patients with Parkinson's disease: a case-controlled study using the rapid eye movement sleep behavior disorder screening questionnaire. BMC Neurol 2013; 13:18. [PMID: 23394437 PMCID: PMC3575252 DOI: 10.1186/1471-2377-13-18] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2012] [Accepted: 02/06/2013] [Indexed: 11/15/2022] Open
Abstract
Background Increasing evidence provides a clear association between rapid eye movement sleep behavior disorders (RBD) and Parkinson’s disease (PD), but the clinical features that determine the co-morbidity of RBD and PD are not yet fully understood. Methods We evaluated the characteristics of nocturnal disturbances and other motor and non-motor features related to RBD in patients with PD and the impact of RBD on their quality of life. Probable RBD (pRBD) was evaluated using the Japanese version of the RBD screening questionnaire (RBDSQ-J). Results A significantly higher frequency of pRBD was observed in PD patients than in the controls (RBDSQ-J ≥ 5 or ≥ 6: 29.0% vs. 8.6%; 17.2% vs. 2.2%, respectively). After excluding restless legs syndrome and snorers in the PD patients, the pRBD group (RBDSQ-J≥5) showed higher scores compared with the non-pRBD group on the Parkinson’s disease sleep scale-2 (PDSS-2) total and three-domain scores. Early morning dystonia was more frequent in the pRBD group. The Parkinson’s Disease Questionnaire (PDQ-39) domain scores for cognition and emotional well-being were higher in the patients with pRBD than in the patients without pRBD. There were no differences between these two groups with respect to the clinical subtype, disease severity or motor function. When using a cut-off of RBDSQ-J = 6, a similar trend was observed for the PDSS-2 and PDQ-39 scores. Patients with PD and pRBD had frequent sleep onset insomnia, distressing dreams and hallucinations. The stepwise linear regression analysis showed that the PDSS-2 domain “motor symptoms at night”, particularly the PDSS sub-item 6 “distressing dreams”, was the only predictor of RBDSQ-J in PD. Conclusion Our results indicate a significant impact of RBD co-morbidity on night-time disturbances and quality of life in PD, particularly on cognition and emotional well-being. RBDSQ may be a useful tool for not only screening RBD in PD patients but also predicting diffuse and complex clinical PD phenotypes associated with RBD, cognitive impairment and hallucinations.
Collapse
Affiliation(s)
- Keisuke Suzuki
- Department of Neurology, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi 321-0293, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|